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Case Presentation 
A 7 year old boy presented to Paediatric Dermatology with a history of white tinges within 
his eyelashes, followed two weeks later by hypopigmented patches and some areas of hair 
loss on the scalp, and an area of cutaneous hypopigmentation on the lower back.   
Four months previously, the patient had experienced acute-onset painless bilateral red eyes 
and reduced visual acuity, which improved with steroid eye drops.  
The patient had remained systemically well throughout, with no fevers, weight loss, sweats, 
fatigue, arthropathy, rash or neurological symptoms. There was no history of preceding 
illness or ocular trauma, no significant past medical history, and no family history of note.   
On examination, there was patchy hypopigmentation within the eyelashes (figure 1) and 
scalp hair, areas of alopecia with some regrowth (figure 2), and roughly symmetrical 
bilateral patchy hypopigmentation of the lower lumbar area (figure 3). Blood tests, including 
a full blood count, antinuclear antibodies, HLA-B27 screen, quantiferon and toxoplasmosis 
serology, showed no abnormalities. An MRI of the brain was also normal. 





Diagnosis Vogt-Koyanagi-Harada disease   
Clinical Course  
The combination of acute panuveitis, poliosis, alopecia and cutaneous hypopigmentation 
was sufficient in this case for a clinical diagnosis of Vogt-Koyanagi-Harada disease. Although 
topical (and later oral) steroids improved the patient’s visual acuity, these were 
discontinued due to raised intraocular pressure. Oral methotrexate (15mg weekly) was 
started as an alternative, which resolved the eye disease and improved the poliosis and 
alopecia. The hypopigmented lumbar patches remain unchanged, 6 months after initial 
presentation.   
Discussion 
Vogt-Koyanagi-Harada disease (VKHD) is a rare systemic autoimmune condition targeting 
melanocytes in different tissues, including the eye, the brain, the inner ear and the skin (1). 
The presentation is variable according to which tissues are affected and the chronological 
course of the disease.  
The diagnosis is made clinically and can be classified as complete, incomplete or probable 
VKHD as dictated by set criteria (2). There are no diagnostic serological or histological 
findings. VKHD is an important diagnosis to make as there is a significant threat of visual 
loss; acutely from retinal detachment, and/or chronically from glaucoma, cataracts and 
choroidal neovascularization. However, these serious and debilitating consequences are 
preventable with prompt diagnosis and treatment. 
Differential diagnosis of the cutaneous signs theoretically includes vitiligo and causes of 
patchy alopecia, and it is therefore critical to ask for a history of uveitis to discriminate from 
these.  Alezzandrini syndrome is a possibly separate, possibly overlapping differential 
diagnosis of VKHD (3).    
There are four classic stages of VKHD. The first is a prodromal stage of non-specific flu-like 
illness. This is followed days later by the second and characteristic acute uveitic phase, 
which gives rise to several weeks of blurred vision and redness. This acute phase can also be 
associated with headache, tinnitus and neck stiffness. A few months later, the disease 
enters the third phase, that of chronic hypo- or de-pigmentation, which affects the eyes and 
skin. In the eyes, depigmentation of the choroid ultimately results in a ‘sunset-glow fundus’. 
Dermatological findings include alopecia, poliosis of the scalp, eyebrows and eyelashes, and 
vitiligo. The lower back is the most classic area affected by hypo or de-pigmentation, as seen 
in this patient. Periumbilical depigmentation (Sugiura’s sign) can also occur at an earlier 
stage, around a month after the onset of uveitis (4). The fourth stage is chronic recurrent 
disease, in which patients can experience flares of uveitis, ocular complications (glaucoma, 
cataracts and choroidal neovascularization) and ongoing dermatological involvement. 
VKHD predominantly affects those of Asian and Hispanic descent. However, this appears to 
be related to ethnic group rather than degree of skin pigmentation, as VKHD is rare in 
African-Americans (5). Although more common in adults (1), VKHD can present in childhood. 
Indeed, VKHD is responsible for an estimated 16% of pediatric uveitis in Saudi Arabia (6). 
Typically, the prognosis of VKHD in children is good (7). However, VKHD presenting under 
the age of 14 appears to result in more aggressive disease with poorer visual outcomes (8).  
Early initiation of high-dose steroid therapy is key in the treatment of VKHD. As evidence for 
treatment in children is limited, adult literature is used as the basis for treatment. Systemic 
prednisone, either oral or intravenous, rapidly improves acute symptoms by resolving 
exudative retinal detachment. In children, a shorter interval between symptoms and 
treatment is linked to better final outcomes of visual acuity (7). Oral steroid therapy should 
be gradually reduced over two years to prevent recurrence (9). Patients with steroid-
resistant disease or steroid intolerance can be treated with methotrexate or other 
antimetabolites as a second line therapy. 
The mechanism underlying VKHD is not fully understood, but is currently considered to be 
an autoimmune process targeting unidentified melanocyte-associated antigens, preceded 
by viral infection (10).  
In summary, VKHD is a serious autoimmune condition that presents with acute uveitis 
followed months later by poliosis, alopecia and vitiligo. Both acute and chronic disease can 
lead to permanent visual loss, which is preventable with early initiation of steroid therapy, 
and recognition of the disease by Paediatric Dermatologists could therefore be important in 
directing therapy. 
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